ATE513561T1 - Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien - Google Patents

Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Info

Publication number: ATE513561T1
Authority: AT; Austria
Prior art keywords: adjuvants; alteration; clip; balance; flu vaccines
Prior art date: 2005-11-04

Application number

AT06808431T

Other languages

English (en)

Inventor

Derek O'hagan

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-04

Filing date

2006-11-06

Publication date

2011-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37897441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-11-06 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE513561T1 publication Critical patent/ATE513561T1/de

Links

239000002671 adjuvant Substances 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
230000004075 alteration Effects 0.000 title 1
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
102000002322 Egg Proteins Human genes 0.000 abstract 1
108010000912 Egg Proteins Proteins 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
238000004113 cell culture Methods 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
241000712461 unidentified influenza virus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT06808431T 2005-11-04 2006-11-06 Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien ATE513561T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73402605P	2005-11-04	2005-11-04
US81247506P	2006-06-08	2006-06-08
PCT/GB2006/004136 WO2007052059A2 (en)	2005-11-04	2006-11-06	Changing th1/th2 balance in split influenza vaccines with adjuvants

Publications (1)

Publication Number	Publication Date
ATE513561T1 true ATE513561T1 (de)	2011-07-15

Family

ID=37897441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06808431T ATE513561T1 (de)	2005-11-04	2006-11-06	Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Country Status (12)

Country	Link
US (1)	US20090047353A1 (de)
EP (1)	EP1951300B1 (de)
JP (1)	JP5363107B2 (de)
AT (1)	ATE513561T1 (de)
AU (1)	AU2006310340B2 (de)
CA (1)	CA2628397C (de)
CY (1)	CY1112895T1 (de)
DK (1)	DK1951300T3 (de)
NZ (1)	NZ568212A (de)
PL (1)	PL1951300T3 (de)
PT (1)	PT1951300E (de)
WO (1)	WO2007052059A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2628152C (en) *	2005-11-04	2016-02-02	Novartis Vaccines And Diagnostics S.R.L.	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2014279A1 (de)	2007-06-22	2009-01-14	Pevion Biotech AG	Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
JP5518041B2 (ja)	2008-03-18	2014-06-11	ノバルティスアーゲー	インフルエンザウイルスワクチン抗原の調製における改良
EP3173097A3 (de)	2009-02-10	2017-07-12	Seqirus UK Limited	Influenzaimpfstoffe mit reduzierten anteilen an squalen
EP2207031A1 (de) *	2009-05-18	2010-07-14	Abbott Biologicals B.V.	Hilfsstoffprüfung für Impfstoffzubereitungen
NZ603918A (en)	2010-05-12	2015-04-24	Novartis Ag	Improved methods for preparing squalene
GB201009273D0 (en) *	2010-06-03	2010-07-21	Glaxosmithkline Biolog Sa	Novel vaccine
CA3007787C (en)	2010-06-03	2020-03-10	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
US9821051B1 (en)	2010-10-28	2017-11-21	Seqirus UK Limited	Reducing hospitalization in elderly influenza vaccine recipients
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
TW201427664A (zh)	2012-11-02	2014-07-16	Pharmacyclics Inc	Ｔｅｃ家族激酶抑制劑佐劑療法
US9885086B2 (en)	2014-03-20	2018-02-06	Pharmacyclics Llc	Phospholipase C gamma 2 and resistance associated mutations
WO2016001907A1 (en) *	2014-07-02	2016-01-07	Prendergast Patrick T	Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
ES2991988T3 (es)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1124013A (zh) *	1993-02-19	1996-06-05	史密丝克莱恩比彻姆公司	含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
ES2370937T3 (es) *	1993-09-13	2011-12-23	Protein Sciences Corporation	Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
CA2312900A1 (en) *	1997-12-02	1999-06-10	Powderject Vaccines, Inc.	Transdermal delivery of particulate vaccine compositions
EP1156781B1 (de) *	1999-02-26	2005-06-08	Chiron Corporation	Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
PT1187629E (pt) *	1999-04-19	2005-02-28	Glaxosmithkline Biolog Sa	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GB9923176D0 (en)	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
US20040109874A1 (en) *	1999-11-10	2004-06-10	Powderject Vaccines, Inc.	Induction of mucosal immunity by vaccination via the skin route
AU2001258476A1 (en) *	2000-04-26	2001-11-07	Biovector Therapeutics	Use of particulate vectors in immunomodulation
ES2319864T3 (es) *	2000-04-28	2009-05-14	St. Jude Children's Research Hospital	Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
GB0025577D0 (en) *	2000-10-18	2000-12-06	Smithkline Beecham Biolog	Vaccine
CA2514667C (en) *	2003-01-30	2013-01-08	Chiron Corporation	Adjuvanted influenza vaccine
CN1764473A (zh) *	2003-03-24	2006-04-26	英特塞尔股份公司	矾与Th1免疫应答诱导佐剂用于增强免疫应答的用途
EP2269638A3 (de) *	2004-05-28	2012-06-13	GlaxoSmithKline Biologicals S.A.	Impfstoffzusammensetzungen mit Virosomen und einem Saponin-Adjuvans
US20070292386A9 (en) *	2004-12-02	2007-12-20	Campbell Robert L	Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
AR054020A1 (es)	2005-03-23	2007-05-30	Glaxosmithkline Biolog Sa	Nuevo uso

2006
- 2006-11-06 NZ NZ568212A patent/NZ568212A/en not_active IP Right Cessation
- 2006-11-06 CA CA2628397A patent/CA2628397C/en not_active Expired - Fee Related
- 2006-11-06 EP EP06808431A patent/EP1951300B1/de not_active Not-in-force
- 2006-11-06 AU AU2006310340A patent/AU2006310340B2/en not_active Ceased
- 2006-11-06 PT PT06808431T patent/PT1951300E/pt unknown
- 2006-11-06 JP JP2008538421A patent/JP5363107B2/ja active Active
- 2006-11-06 PL PL06808431T patent/PL1951300T3/pl unknown
- 2006-11-06 AT AT06808431T patent/ATE513561T1/de active
- 2006-11-06 WO PCT/GB2006/004136 patent/WO2007052059A2/en not_active Ceased
- 2006-11-06 DK DK06808431.8T patent/DK1951300T3/da active
- 2006-11-06 US US12/092,146 patent/US20090047353A1/en not_active Abandoned
2011
- 2011-09-15 CY CY20111100896T patent/CY1112895T1/el unknown

Also Published As

Publication number	Publication date
CA2628397A1 (en)	2007-05-10
PT1951300E (pt)	2011-09-05
CA2628397C (en)	2013-08-20
WO2007052059A2 (en)	2007-05-10
AU2006310340A1 (en)	2007-05-10
PL1951300T3 (pl)	2012-03-30
US20090047353A1 (en)	2009-02-19
JP2009514842A (ja)	2009-04-09
EP1951300A2 (de)	2008-08-06
WO2007052059A3 (en)	2007-08-30
JP5363107B2 (ja)	2013-12-11
NZ568212A (en)	2012-03-30
DK1951300T3 (da)	2011-10-03
AU2006310340B2 (en)	2011-02-10
EP1951300B1 (de)	2011-06-22
CY1112895T1 (el)	2016-04-13

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1951300

Country of ref document: EP

Publication	Publication Date	Title
CY1112895T1 (el)	2016-04-13	Μεταβολη της ισορροπιας τη1/τη2 στα διαχωρισμενα αντιγριπικα εμβολια με ανοσοενισχυτικα
CY1118492T1 (el)	2017-07-12	Φαρμακοτεχνικες μορφες εμβολιου norovirus
NO20054608L (no)	2005-12-07	Influensavirusvaksine
DK2468300T3 (da)	2018-01-29	Vaccinesammensætning indeholdende syntetisk adjuvant
EA200801756A1 (ru)	2009-02-27	Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
DK1951299T3 (da)	2012-04-02	Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
ATE491467T1 (de)	2011-01-15	Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EA200900784A1 (ru)	2009-12-30	Вакцины, включающие антиген из четырех штаммов вируса гриппа
NO20023829L (no)	2002-08-13	Proteosom influensavaksine
WO2007095320A3 (en)	2007-10-25	Hpv antigens, vaccine compositions, and related methods
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
EA201071087A1 (ru)	2011-04-29	Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
CY1113546T1 (el)	2016-06-22	Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
EA200970271A1 (ru)	2010-02-26	Получение вакцин против вируса гриппа без использования куриных эмбрионов
EA200801798A1 (ru)	2009-06-30	Виросомоподобные везикулы, содержащие антигены, производные от gp41
CY1120430T1 (el)	2019-07-10	Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA201391515A1 (ru)	2014-05-30	Инактивированная вакцина вируса денге
AR060565A1 (es)	2008-06-25	Vacuna para la gripe aviaria y metodos de uso
EA201891124A2 (ru)	2018-10-31	Новые мукозные адъюванты и системы доставки
EA201892735A1 (ru)	2019-05-31	Состав вакцины против hiv
CL2006000880A1 (es)	2009-08-07	Composicion inmunogena para causar una respuesta inmunologica contra una especie helicobacter y circovirus porcino que comprende antigenos de dichos patogenos; metodo para inducir una respuesta inmunologica contra dichos patogenos; kit para preparar la composicion inmunogena.
WO2008134643A3 (en)	2008-12-18	Trypanosoma antigens, vaccine compositions, and related methods
MX2009007572A (es)	2009-10-13	Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
EA200801250A1 (ru)	2008-12-30	Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа
CL2011002994A1 (es)	2012-07-20	Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.